This IGF-1 level is literally in acromegaly territory, and would certainly expose someone to some level of long-term consequences if this dosage were used year round, for many years on end [R]
You have to be enrolled in a Medicare Part D Plan (Medicares prescription drug plan that requires a monthly premium) AND you cannot have received a GLP-1 through that Part D plan
GSH deficiency results in the activation of von Willebrand Factor (Ibrahim et al., 2004) and in the accumulation of ROS, which affect clotting and platelet activation, impair endothelial function, and predispose to the risk of thrombotic events (Violi et al., 2017): notably, hypercoagulation is a prominent life-threatening complication in COVID-19 patients (Giardini et al., 2020)

Key questions to discuss include: Whether you meet NHS criteria for GLP-1 prescription (type 2 diabetes or obesity with complications) The evidenceor lack thereoffor GLP-1 use specifically in Hashimoto's management Potential interactions between GLP-1 medications and thyroid hormone replacement How GLP-1 therapy might affect your thyroid function monitoring schedule Alternative evidence-based approaches to managing metabolic symptoms in Hashimoto's The costs and practicalities of private prescription if NHS funding is not available Contraception requirements if you are of childbearing potential (GLP-1 medications should be avoided in pregnancy and breastfeeding) Your GP may recommend optimising your current thyroid management first , ensuring your levothyroxine dose is appropriate and that you are not over- or under-replaced